A STUDY ON THE DETAILED DESCRIPTION OFFIFTH DISEASE& MYSTERY REGARDING THE NON-PHARMACOLOGICAL TREATMENT OFFIFTH DISEASE

Fifth disease is a mild rash illness, caused due to parvovirus B19. This will be mainly seen in children compare to adults. Other names for this include: ErythemaInfectiosum (EI), Slapped cheek syndrome. Epidemics of erythema infectiosum mainly occurs in late winter or early spring. Tests for this include specific parvovirus B19 IgM antibody. IgM antibodies usually founds within 7 to 10 days of virus exposure, the remain measures are from 2 to 3 months after exposure to virus. Symptoms mainlyincludes rash, headache, fatigue, low-grade fever. However,there is no vaccine or medicine that prevent parvovirus B19 infection. Adults who have symptoms of joint pain and swelling may need rest, to alter their activities. Andtake Nonsteroidal anti-inflammatory drugs like Aspirin, Ibuprofen, or Naproxen sodium. Patients who are suffering with chronic parvovirus arthritis occasionally benefit from drugs such as hydroxychloroquine and corticosteroids and also, they want to avoid dairy products, Sweets and sugar. They want to increase their fluid intake and vitamin c supplements to improve their immune system.

Fifth’s disease in children and role of community health officer

Fifth’s disease it is more common condition in children’s age group of 5 to 15 years old and some time it will be sever in pregnant women and individual with compromised immune system. It is also named as erythema infectiosum, slapped cheek disease and most common cause is par virus B19. This is airborne virus leads to spread through saliva and respiratory secretions among children who are in elementary school period. This condition is more common during winter, spring early summer but it may spread at any time have been happens at any age group. The most common clinical symptoms are like distinctive red rash on the face that makes a child appear to have a slapped cheek and a few days later, the rash spreads down to the trunk, arms, and legs and it usually lasts 1 to 3 weeks and along with we can see head ache, fatigue, low-grade fever, sore throat, nausea, runny nose. In this kind of conditions at community level the community health officer who is in-charge of health and wellness center must diagnose the disease by clinical examination of the child and send for the specific clinical antibody test. To have relieve from those clinical symptoms must use acetaminophen that is Tylenol and intravenous immunoglobulin (IVIG) can be administered. This treatment is usually reserved for severe, life-threatening cases. The community health officer must advice non pharmacological methods like tacking adequate rest, drinking plenty of water and adequate nutrition, supplementary fluids.

Prevalence and Phylogenetic Analysis of Parvovirus (B19V) among Blood Donors with Different Nationalities Residing in Qatar

Human parvovirus (B19V) is the causative agent of erythema infectiosum in children and is linked to a wide range of clinical manifestations. Studies related to B19V prevalence in the Middle East and North Africa (MENA) region and other parts of Asia are very scarce. The objectives of this study were to estimate the seroprevalence (anti-B19V IgM and IgG), the viremia rate (B19V DNA), and the circulating genotypes of B19V among blood donors in Qatar. Methods: Donors’ blood samples (n = 5026) from different nationalities, mainly from the MENA region and South East Asia, were collected from 2014–2016. Samples were tested for the B19V DNA using RT-PCR. Furthermore, 1000 selected samples were tested to determine the seroprevalence of B19V antibodies using enzyme-linked immunosorbent assay (ELISA). Genotyping was performed on 65 DNA positive samples by sequencing of nested PCR fragments (NS1-VP1u region, 927 nt). Results: Only 1.4% (70/5026) of the samples had detectible B19V DNA in their blood. B19V DNA prevalence statistically decreased with age (p = 0.03). Anti-B19V IgG was detected in 60.3% (561/930) of the tested samples, while only 2.1% (20/930) were IgM-positive and 1.2% (11/930) were both IgM- and IgG-positive. B19V genotyping showed a predominance of Genotype 1 (100%). Sequence analysis of the NS1-VP1u region revealed 139 mutation sites, some of which were amino acid substitutions. Conclusion: Our results indicated a relatively high seroprevalence of B19V in Qatar. Most importantly, B19 DNA was detected among Qatari and non-Qatari blood donors. Therefore, blood banks in Qatar might need to consider screening for B19V, especially when transfusion is intended for high-risk populations, including immunocompromised patients.

Comprehensive surveillance data suggest a prominent role of parvovirus B19 infection in Belarus and the presence of a third subtype within subgenotype 1a

Human parvovirus B19 (B19V) infection is not notifiable in Belarus and its most common clinical presentation erythema infectiosum (EI) is often difficult to distinguish from other exanthematous diseases. The objective of this study was to provide comprehensive data about EI epidemiology in Belarus based on the serological and molecular investigation of samples from measles and rubella discarded cases collected between 2005 and 2019. Overall, 4919 sera were investigated for IgM antibodies against B19V and the positive cases were analysed according to year, season and age. B19V DNA was amplified by PCR in a total of 238 sera from all over the country, and sequenced for phylogenetic analyses. B19V infection was confirmed in 1377 (27.8%) measles and rubella discarded cases. Two high incidence periods and a seasonal increase of EI between mid-February to mid-July were identified. Children from 4 to 6 and from 7 to 10 years of age represented the largest groups of patients (22.51% and 22.66% of all cases, respectively), followed by adults between 20 and 29 years of age (14.23%). Among the 238 B19Vs sequenced, one belonged to subgenotype 3b and 237 to subgenotype 1a with 81 (34.2%) clustering with subtypes 1a1 and 153 (64.6%) with 1a2. Three strains (1.2%) formed an additional, well-supported cluster suggesting the presence of another subtype of 1a, tentatively named 1a3. The epidemiological and molecular analyses highlighted not only the prominent role of B19V in exanthematous diseases in Belarus, but also suggested a previously underestimated diversity of subgenotype 1a sequences with a third subtype 1a3.

A literature review on the parvovirus B19 infection in sickle cell anemia and β-thalassemia patients

Background Parvovirus B19 is the causative agent for erythema infectiosum, and also as a potentially life-threatening infectious agent, it is mainly presented in high erythrocyte turnover patients. Sickle cell disease (SCD) is an inherited monogenic hematological disorder resulting from the mutations in the hemoglobin β-chain gene. Thalassemia is a hereditary hematological syndrome that happens in consequence of deficiencies in the production of one or more globin chains. We summarize current knowledge about the prevalence rates of the parvovirus B19 infection in sickle cell anemia and thalassemia patients. Methods Several online databases were searched including, Scopus, EMBASE, Web of Science, Google Scholar, and PubMed, which were performed amidst 2009–2019 by using distinct keywords: “Thalassemia,” “Parvovirus,” “Anemia,” “Sickle cell anemia,” “parvoviridae,” “parvoviridae infection,” and “parvovirus B19.” Results Search results indicated 4 and 7 studies for the prevalence of the parvovirus B19 in β-thalassemia and SCD, respectively. Among the β-thalassemia patients, the B19V seroprevalence for IgG and IgM were ranged from 18.2–81% and 14.5–41.1%, respectively; meanwhile, B19V DNA positively results was 4–15.3%. Moreover, in the SCD group, the extent of B19V IgG was varied from 37.6 to 65.9% and that of IgM was in a range of 2.9–30%, and the DNA detection rate was 4–54%. Conclusion B19V seroprevalence changes in several conditions including, different epidemiological features, socio-economic status, and overpopulation. Age can expand the incidence of anti-B19V IgG/IgM in SCD and beta-thalassemia patients. Reinfection and diverse genotypes are relevant factors in the seroprevalence of B19v. The patients’ immunological-hematological station and higher abundance of transfusions can affect the B19V seroprevalence in SCD and beta-thalassemia group. Further investigations in this field could be suggested to better understand the virus distribution in this susceptible population of patients.